Conditions: Psoriasis
Keywords: Psoriasis
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 8
Healthy volunteers: no

Brief summary:
In this study, we will evaluate clinical activity, safety, tolerability, pharmacokinetics, pharmacodynamics, and immunogenicity of 5 LY2525623 dosing groups compared to placebo in adults with plaque psoriasis.

Detailed description:

Arms:
arm 1: None arm 2: None arm 3: None arm 4: None arm 5: None arm 6: None arm 7: None

Interventions: intervention 1: LY2525623 Intravenous intervention 2: LY2525623 Subcutaneous intervention 3: Placebo Intravenous intervention 4: Placebo Subcutaneous
Intervention descriptions: intervention 1: administered intravenously at randomization and every 2 weeks for 6 weeks intervention 2: administered subcutaneously at randomization and every 2 weeks for 6 weeks intervention 3: administered intravenously at randomization and every 2 weeks for 6 weeks intervention 4: administered subcutaneously at randomization and every 2 weeks for 6 weeks

Protocol document: